华熙生物的下场无疑将"战况"再度升级，叠加此前，华熙生物炮轰"玻尿酸过时论"，华熙生物的此番下场战队，也被市场解读为是护肤成分市场中玻尿酸与 重组胶原蛋的路线之争。 出品｜搜狐财经 作者｜冯圆圆 端午假期期间，巨子生物产品造假风波再度升级。 6月1日晚间，华熙生物发文表示支持大嘴博士维护消费者权益；同时，已对大嘴博士发来的相关资料进行评估和第三方测试，且已得到结果。并表示，在其 公布结果之前，希望相关企业主动面对问题。 另一方面，巨子生物也在3小时后，发布了机构的道歉声明，同时表示对某上市公司的发言感到震惊又痛心。 一来一往，双方的发言均将矛头指向了对方。 可复美造假事件再升级 6月2日，知名大V大嘴博士再度发文"炮轰"巨子生物，剑指巨子生物对其合作的检测机构施压；同时表示，自己已联系不到当时负责检测的负责人。 （图片来源：大嘴博士颜究所） 大嘴博士的此番言论，再度将双方的"骂战"升级。 回顾时间线，5月24日，知名大V大嘴博士在微博发布了一则8分钟的视频，直指巨子生物旗下大单品可复美胶原蛋白精华的胶原蛋白含量造假。 （图片来源：大嘴博士微博） 据大嘴博士表示，巨子生物大单品可复美胶原蛋白精华中重组胶原蛋白的 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [31]. Core Insights - The MSCI China Healthcare Index has increased by 27.6% since the beginning of 2025, outperforming the MSCI China Index by 14.5% [2]. - The international competitiveness of Chinese innovative drugs is being demonstrated through significant overseas licensing deals, reflecting a strong market presence [2]. - The report anticipates a valuation recovery in the pharmaceutical industry by 2025, driven by factors such as overseas licensing transactions, optimization of domestic procurement policies, and the implementation of new medical insurance categories [5]. Summary by Sections 1. **Industry Research - Medical Insurance Negotiations** - Continued support for innovation and recovery in overseas R&D demand [5]. 2. **Industry Research - Medical Equipment** - Expected recovery in bidding for medical devices and fruitful outcomes from innovative drug overseas transactions [5]. 3. **Industry Research - Medical Insurance Directory** - The results of adjustments to the medical insurance directory are expected to continuously support innovation [5]. 4. **Industry Research - Ongoing Policy Efforts** - Positive outlook for valuation rebound due to sustained policy support [5]. 5. **Industry Research - New Medical Insurance Categories** - The introduction of new medical insurance categories is expected to open up domestic payment space for innovative drugs [5]. 6. **Industry Research - Valuation Recovery** - The industry is poised for a valuation recovery, with several companies recommended for purchase [5]. 7. **Industry Research - Drug Pricing Policies** - Drug pricing policies are expected to be optimized, with accelerated commercialization of medical AI [5]. 8. **Industry Research - Anticipated Drug Procurement Policy Optimization** - Expectations for the implementation of an "innovative drug directory" [5]. 9. **Industry Research - 2024 Performance Review** - Innovative drugs are expected to dominate the market [5].

Investment Rating - The report maintains an "Add" rating for the industry [1] Core Insights - Lin Qingxuan, a leading domestic high-end skincare brand, has officially submitted its application to the Hong Kong Stock Exchange, marking a new chapter in its capitalization [4][9] - The company has experienced rapid growth in recent years, with revenue increasing from 691 million RMB in 2022 to 1.21 billion RMB in 2024, representing a CAGR of 32.3% [12][20] - Lin Qingxuan ranks first among domestic high-end skincare brands in China by retail sales, and is the only domestic brand in the top 15 high-end skincare brands [27] Industry Overview - The high-end domestic skincare market is characterized by strong performance from brands like Lin Qingxuan, which focuses on anti-aging and tightening products [4][9] - The company's flagship product, Camellia Oil, has seen significant growth, with a CAGR of 43% from 2022 to 2024 [20][25] - Online sales channels have doubled, with online revenue accounting for 59.1% of total revenue in 2024, compared to 40.8% from offline channels [25][26] Financial Performance - Lin Qingxuan's net profit improved from a loss in 2022 to 186 million RMB in 2024, with a net profit growth of 121% year-on-year in 2024 [12][20] - The company's gross margin has increased from 78% in 2022 to 82.5% in 2024, reflecting improved profitability [12][18] Market Dynamics - Recent promotional events, such as the 618 shopping festival, have highlighted the strong performance of domestic beauty brands, with Lin Qingxuan and others gaining significant market share [28] - The report suggests that Lin Qingxuan's successful market positioning and product innovation will continue to drive growth in the high-end skincare segment [4][29]

Group 1 - Hantse Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with ICBC International as the sole sponsor [1] - The company aims to raise capital for its operations and expansion in the biopharmaceutical sector [1] Group 2 - Xiaomi's founder Lei Jun stated that the new Xiaomi YU7 car will not be priced at 235,900 yuan as rumored, and the automotive business is expected to achieve profitability in the second half of this year [5] - The total budget for the intelligent driving research and development of YU7 is set at 3.5 billion yuan, indicating a significant investment in the automotive sector [5] Group 3 - Neuralink, a brain-computer interface company founded by Elon Musk, has completed a $650 million Series E funding round with participation from major investors [18] - The funding will support the company's ongoing development and innovation in brain-machine interface technology [18] Group 4 - Toyota Group announced plans to privatize Toyota Automatic Loom Works through a series of transactions involving its subsidiaries, aiming to accelerate its transformation into a mobility company [19] - The investment for this privatization effort includes approximately 180 billion yen from Toyota Real Estate and 70 billion yen from Toyota Motor for purchasing non-voting preferred shares [19] Group 5 - Spotify has been fined 58 million Swedish Krona for data protection violations, as determined by the Stockholm Court of Appeal [20] - The fine is a result of Spotify's failure to comply with the EU's General Data Protection Regulation regarding the handling of data subject rights [20]

Group 1 - The Chinese government has expressed strong opposition to the U.S. claims of violations regarding the Geneva economic talks, stating that pressure and coercion are not the correct ways to engage with China [2] - The U.S. President has announced an increase in tariffs on imported steel and aluminum from 25% to 50%, effective June 4, 2025 [2] - The South Korean presidential election results show Lee Jae-myung from the Democratic Party received 49.42% of the votes, marking the start of his presidential term [2] Group 2 - The Chinese Ministry of Commerce has urged the EU to correct its proposed restrictions on Chinese companies participating in public procurement for medical devices, indicating that China will closely monitor the EU's actions [3] - The Ministry of Industry and Information Technology has launched a campaign to promote the use of new energy vehicles in rural areas, including tax reductions and infrastructure improvements [3] Group 3 - The Shenzhen Stock Exchange has announced periodic adjustments to its index samples, with several companies being added to various indices, effective June 16 [4] Group 4 - Local securities regulatory bodies are increasing their focus on "small essays" related to the capital market, aiming to collect leads and suggestions to improve the market environment [5] - The A-share market saw a positive performance with major indices rising, driven by financial stocks and new consumption themes, with the Shanghai Composite Index closing at 3361.98 points, up 0.43% [5] - Stablecoins have become a focal point for analysts, with numerous related reports and events being held recently [5] Group 5 - The insurance sector has increased its equity investments, with the stock market value of the life insurance industry reaching 2.65 trillion yuan, representing an 8.43% allocation [6] - Xiaomi's founder revealed that the pricing for the new Xiaomi YU7 will be confirmed shortly, and the company is actively developing capabilities in the automotive sector [6] - NIO reported Q1 2025 revenue of 12.035 billion yuan, up from 9.909 billion yuan in the same period last year, but with an increased adjusted net loss [6] Group 6 - Seres reported May sales of 36,500 vehicles, a year-on-year increase of 13.19%, with cumulative sales of the AITO M9 reaching 50,500 units, up 19.46% year-on-year [7] - The Pang Donglai Group achieved sales exceeding 10 billion yuan, with supermarket sales surpassing 5.5 billion yuan [7] Group 7 - The U.S. stock market saw all three major indices rise, with the Dow Jones increasing by 0.51% to 42,519.64 points, marking a four-day winning streak [7] - The OECD has revised its global economic growth forecasts for 2025 and 2026 down to 2.9% [7] - Japan's 10-year government bond auction saw a significant increase in demand, with the bid-to-cover ratio rising to 3.66, the highest since April 2024 [7] Group 8 - The competition between Huaxi and Juzhi Biotech has intensified, with regulatory bodies now involved in the investigation of the product testing controversy that began in late May [8] - Zong Fuli is reportedly implementing a dual strategy of factory management and expansion in the beverage sector, indicating a significant shift in operational strategy [8]

Group 1 - The competition between two female billionaires in the medical beauty industry is intensifying, with Huaxi Biological and Juzhi Biological exchanging heated statements regarding the composition of collagen products [3] - Huaxi Biological accused an unnamed company of using online marketing tactics and threatened to disclose testing results if issues are not addressed [3] - Juzhi Biological responded by criticizing Huaxi Biological for making malicious accusations and emphasized the distinction between collagen and "recombinant" collagen [3] Group 2 - Xiaomi's founder Lei Jun announced that the pricing for the new Xiaomi YU7 will be determined 1-2 days before its sale, and the automotive business is expected to achieve profitability in Q3 or Q4 of this year [3][4] - Xiaomi has invested a total of 3.5 billion yuan in the development of intelligent driving for the YU7, positioning itself as a leader in the industry [4] Group 3 - NIO is undergoing organizational changes to enhance operational efficiency, with a focus on careful evaluation of R&D projects to ensure only necessary initiatives are pursued [8] - The company has implemented a more rigorous project approval process, resulting in only about half of the 500 proposed projects being approved [8] Group 4 - The sales revenue of Pang Donglai Group has exceeded 10.176 billion yuan as of June 2, 2025, with the supermarket segment generating the highest sales of approximately 5.566 billion yuan [6] - Neta Auto has been fined 33,000 yuan for violating labor protection regulations, highlighting compliance issues within the automotive sector [6] Group 5 - The global smartphone market has seen a growth slowdown, with only a 0.2% increase in Q1 2025, totaling 296.9 million units shipped [19] - Samsung leads the market with 60.5 million units shipped, followed by Apple with 55 million units, and Xiaomi with 41.8 million units, maintaining a 14% market share [20]

Group 1 - The European Union plans to restrict Chinese companies' participation in public procurement of medical devices, reflecting an escalation in economic friction between China and Europe in the high-end manufacturing sector [1] - The Chinese Ministry of Commerce emphasizes the importance of adhering to WTO rules and maintaining fair competition principles, urging the EU to correct its actions and expressing a commitment to protect the legitimate rights of Chinese enterprises [1] Group 2 - Lepu Medical announced that its self-developed polylactic acid facial filler, known as "童颜针" (Youthful Needle), has received registration approval from the National Medical Products Administration (NMPA), marking a significant milestone for the company in the dermatology field [2] - The approval allows Lepu Medical to enter the competitive medical aesthetics market, potentially providing new growth opportunities, although the market already has several similar products, raising concerns about product homogeneity and the need for validation of clinical performance and brand strength [2] Group 3 - Huaxi Biological responded to recent controversies regarding "recombinant collagen," clarifying that its opposition is to the misuse of terminology rather than to collagen research and industrial transformation [3] - The company emphasizes the importance of product quality and seeks to address issues within the industry, highlighting the need for trust to be built on empirical data rather than concept misuse [3]

证券研究报告·行业跟踪周报·商贸零售 证券分析师 张家璇 商贸零售行业跟踪周报 林清轩正式递表港交所，国产高端护肤开启 资本化新篇章 增持（维持） [Table_Tag] [投资要点 Table_Summary] 2025 年 06 月 04 日 证券分析师 吴劲草 执业证书：S0600520090006 wujc@dwzq.com.cn 证券分析师 石旖瑄 执业证书：S0600522040001 shiyx@dwzq.com.cn 执业证书：S0600520120002 zhangjx@dwzq.com.cn 证券分析师 阳靖 执业证书：S0600523020005 yangjing@dwzq.com.cn 证券分析师 郗越 执业证书：S0600524080008 xiy@dwzq.com.cn 研究助理 王琳婧 执业证书：S0600123070017 wanglj@dwzq.com.cn 行业走势 -14% -8% -2% 4% 10% 16% 22% 28% 34% 40% 46% 2024/6/3 2024/10/1 2025/1/29 2025/5/29 商贸零售 沪深300 相关研究 《酒店集团业 ...

Group 1: Gold Market Insights - Despite a slight strengthening of the dollar, the mainstream market expectation is that the Federal Reserve will initiate a rate cut cycle by 2025, supported by recent moderate inflation data, which is a core driver for gold prices [1] - As the interest rate hike cycle approaches its end, the trend of declining real interest rates is clear, reducing the opportunity cost of holding gold as a non-yielding asset, thus solidifying the mid-term bullish outlook [1] - The expansion of the U.S. fiscal deficit raises concerns about the sustainability of U.S. debt, coupled with the Biden administration's tough stance on international trade, leading to systemic doubts among investors regarding the dollar and U.S. assets [1] Group 2: Brain-Computer Interface Market - Hubei Province has included invasive brain-computer interface surgeries in medical insurance, priced at 6,552 yuan (approximately 936 USD), significantly lower than Neuralink's cost of 50,000 USD, highlighting a competitive advantage [1] - The price difference reflects not only lower manufacturing and surgical costs but also China's systematic support for brain-computer interface technology in medical policies, which is expected to stimulate large-scale market demand, particularly in rehabilitation, elderly care, and treatment of neurological diseases [1] - Advanced flexible electrode technology, significantly smaller than a human hair, enables paralyzed patients to control games with their minds, while Brain Tiger Technology's "North Brain No. 1" allows epilepsy patients to operate WeChat and Taobao through brain control, showcasing technological advancements comparable to Neuralink [1] Group 3: Collagen Market Dynamics - The controversy surrounding Giant Bio's "Kefumei" product's collagen content is fundamentally a market competition between two technological routes: hyaluronic acid vs. recombinant collagen [1] - Huaxi Bio's active involvement and direct questioning of the capital market's excessive hype around the "recombinant collagen" concept indicate its defensive posture amid profit declines and industry shifts [1] - According to Frost & Sullivan, the overall collagen market is projected to reach 173.8 billion yuan by 2027, significantly surpassing the current scale of the hyaluronic acid industry, with a compound annual growth rate exceeding 50% [1] Group 4: Dairy Industry Challenges - Bright Dairy is facing a structural downturn in the industry characterized by weak consumer demand and intensified price wars, coupled with conservative internal business strategies, leading to a decline from being the "first stock in dairy" to a marginal competitor [3] - Although it maintains a leading position in the low-temperature milk sector, its market share is being closely approached by Yili and Mengniu, with emerging brands continuously eroding its market share [3] - For investors, this indicates that Bright Dairy currently lacks a stable competitive moat and core growth drivers, and without structural transformation, its long-term value will continue to be eroded [3] Group 5: Hair Care Market Trends - The hair care market is expected to grow from 22 billion yuan in 2025 to 50 billion yuan by 2030, with a compound annual growth rate of 15.3%, significantly outpacing the overall personal care industry [5] - The user base is projected to exceed 300 million, with young people, women, and postpartum groups being the main driving forces, as consumption scenarios expand from simple hair loss prevention to "daily care + precise repair + digital experience" [5] - AI scalp detection and genetic screening are creating personalized solutions, significantly improving user retention rates, with repurchase rates reaching over 45% [5]

Core Insights - The 2024 China Cosmetics Yearbook provides a comprehensive overview of the cosmetics industry in China, highlighting a slight decline in market size due to economic conditions and a structural adjustment within the industry [1][10] - Regulatory measures are being strengthened, with policies like the "Cosmetics Inspection Management Measures" promoting compliance and safety in the industry [1][10] - Consumer demand is shifting towards efficacy and precision, with significant growth in categories such as sensitive skin care, anti-aging, and whitening products, while the market for anti-hair loss products has decreased by 35.6% due to saturation [1][10] Market Overview - The overall market size for the cosmetics industry in 2024 is expected to be impacted by economic fluctuations, with local brands like Proya, Kefu Mei, and Winona gaining traction through technological innovation and multi-channel marketing [1][2] - Online sales channels, particularly Douyin and Taobao, are becoming critical for revenue generation, with live streaming and influencer collaborations reshaping the consumer purchasing journey [1][2] - The essence/serum market has reached a scale of 114.83 billion yuan, growing by 13.61%, making it the largest category in skincare [1][2] Competitive Landscape - Domestic brands are performing well, leveraging technology and comprehensive marketing strategies to establish themselves in the mainstream market [1][2] - International brands maintain a stronghold in the high-end market, with brands like La Mer and Helena Rubinstein reinforcing their positions through department stores and duty-free channels, although they face increasing competition from local high-end lines [2][10] Future Trends - The report indicates that scientific communication, biotechnology, and globalization will be key drivers for industry growth, necessitating companies to build differentiated competitive advantages through compliance, technological breakthroughs, and consumer education [2][10] - The "silver economy" and the rise of ingredient-conscious consumers are influencing product development and marketing strategies, emphasizing the need for brands to adapt to changing consumer preferences [1][2] Research and Development - Innovations in raw materials and the "medical-research co-creation" model are becoming focal points, with companies like Giant Bio and Betainy enhancing product efficacy through patented ingredients and clinical collaborations [2][10] - The industry is accelerating its green transformation, with sustainable packaging and low-carbon production receiving policy support [2][10] Expert Insights - The yearbook is recognized for its depth in industry analysis and scientific communication, providing valuable insights into market trends and regulatory developments [7][8] - Experts emphasize the importance of integrating scientific research with product development to ensure safety and effectiveness, particularly in sensitive skin care and anti-aging products [14][18]